SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:15262.
  • 2
    Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:329.
  • 3
    Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591602.
  • 4
    Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:15016.
  • 5
    Aronica E, Gorter JA, Redeker S, et al. Localization of breast cancer resistance protein (BCRP) in micro vessel endothelium of human control and epileptic brain. Epilepsia 2005;46:84957.
  • 6
    Sisodiya SM, Lin W-R, Squier MV, et al. Multidrug-resistance protein 1 in focal cortical dysplasia. Lancet 2001;357:423.
  • 7
    Sisodiya SM, Lint WR, Harding BN, et al. Novartis Found Symp 2002;243:16774.
  • 8
    Van Vliet E, Redeker S, Aronica E, et al. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia 2005;46:15691580.
  • 9
    Volk HA, Burkhardt K, Potschka H, et al. Neuronal expression of the drug efflux transporter p-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 2004;123:7519.
  • 10
    Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:14802.
  • 11
    Volk HA, Potschka H, Löscher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004;58:6779.
  • 12
    Volk HA, Loscher W. Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of p-glucoprotein compared with rats with drug-responsive seizures. Brain 2005;128:135868.
  • 13
    Potschka H, Löscher W. In vivo evidence for p-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 2001;42:123140.
  • 14
    Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce p-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002;22:58339.
  • 15
    Potschka H, Volk HA, Loscher W. Pharmacoresistance and expression of multidrug transporter p-glycoprotein in kindled rats. Neuroreport 2004;15:165761.
  • 16
    Luurtsema G, Molthoff CF, Windhorst AD, et al. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nuclear Med Biol 2003;30:74751.
  • 17
    Kortekaas R, Leenders KL, Van Oostrom JCH, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57:1769.
  • 18
    Bart M, Antoon TM, Willemsen HJM, et al. Quantitative assessment of p-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. NeuroImage 2003;20:177582.
  • 19
    Tan NC, Heron SE, Scheffer IE, et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004;63:10902.
  • 20
    Sills GJ, Kwan P, Butler E, et al. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002;3:42732.
  • 21
    Baars C, Löscher W, Leeb T, et al. Polymorphic variants of the multidrug resistance gene MDR1a and response to antiepileptic drug treatment in the kindling model of epilepsy. Eur J Pharmacol 2006;550:5461.
  • 22
    Rambeck B, Jürgens UH, May TW, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006;47:68194.
  • 23
    Summers MA, Moore JL, McAuley JW, et al. Use of verapamil as a potential p-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother 2004;38:16314.
  • 24
    Iannetti P, Spalice A, Parisi P. Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005;46:9679.
  • 25
    Mazarati A, Bragin A, Baldwin R, et al. Epileptogenesis after self-sustaining status epilepticus. Epilepsia 2003;43(suppl 5):7480.
  • 26
    Clinckers R, Smolders I, Meurs A, et al. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 2005;314:72531.
  • 27
    Van Vliet EA, Van Schaik R, Edelbroek PM, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006;47:67280.
  • 28
    Brandt C, Bethmann K, Gastens AM, et al. The multidrug transporter hypothesis of drug resistance in epilepsy: proof-of-principle in a rat model of temporal lobe epilepsy. Neurobiol Dis 2006;24:20211.